While translocation-induced enhancer hijacking has been reported in several tumors (e.g. IgH-MYC in lymphoma)36, the mechanisms by which a translocation-induced enhancer activates a target oncogene and leads to transformation remain unclear. This evidence concerns the gene MYC and lymphoma.